SCYNEXIS Stock

SCYNEXIS EBIT Growth

The Year-over-Year EBIT Growth of SCYNEXIS (SCYX) as of Aug 6, 2026 is -151.08 %. In the previous year, Year-over-Year EBIT Growth was 184.74 % — a change of -181.78% (lower).

EBIT Growth

-151.08 %

YoY

-181.78%

Last updated:

Year-over-Year EBIT Growth of SCYNEXIS is 2026 -151.08 % . Year-over-Year EBIT Growth of SCYNEXIS was 2025 184.74 % . It decreases by -181.78% lower compared to the previous year.
Access this data via the Eulerpool API

SCYNEXIS Stock analysis

What does SCYNEXIS do? SCYNEXIS Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for serious infectious diseases and cancer. The company was founded in 2000 and is headquartered in New Jersey, USA. SCYNEXIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCYNEXIS stock

Year-over-Year EBIT Growth of SCYNEXIS is -151.08 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth SCYNEXIS since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's SCYNEXIS historically and in real time.

Access this data via the Eulerpool API

Growth — SCYNEXIS

All Key Metrics — SCYNEXIS